Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma

Inclusion Criteria: * Presence of suspicious lesion of the pancreas consistent with pancreatic adenocarcinoma. Cytological confirmation is not required. * Patients preparing to receive therapy for pancreas cancer, including patients enrolled in NCT01413022 * Patient must be 18 years or older * Patient must have a life expectancy of more than 6 months and performance status of 2 or less * Patient must be able to understand and willing to sign an approved written informed consent document * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the length of the study * Patients enrolled in the Clinical trials.gov# NCT01413022 trial must meet both studies eligibility criteria. Exclusion Criteria: * Patient must not have had prior resection for pancreatic adenocarcinoma. * Patient must not have a history of other malignancy less than or equal to 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix * Patient must not be unable to receive a PET-MRI scan due to renal function, allergy or other problem with receiving or tolerating an MRI scan, etc. All patients will fill out a standard MRI screening form. * Patients must not have a blood glucose of greater than or equal to 200mg/dL at the time of PET-MRI or if a patient is diabetic and glucose is not controlled. At the discretion of the PI and the authorized user and with their approval prior to 2-\[18\]fluoro-2-deoxy-D-glucose (FDG) injection, patients with blood glucose ≥ 200 mg/dL may participate in the study. * Patient must not be pregnant and/or breast feeding